Table 1. Demographic, anamnestic and clinical characteristics of the participants receiving ID or IM vaccine.
| |
Vaccine route of administration and antigen dose |
|
|
|---|---|---|---|
| Intradermal 9 µg | Intramuscular 15 µg | p-value | |
| Median age (IQR, years) |
47 (35.7–52.2) |
48.7 (37–53.9) |
0.345 |
| Male sex |
20 (71.5%) |
17 (65.4%) |
0.771 |
| Pandemic influenza vaccination during the 2009/10 season |
10 (35.7%) |
10 (38.5%) |
1 |
| Seasonal influenza vaccination during the 2009/10 season |
13 (46.4%) |
10 (38.5%) |
0.593 |
| Subjects on HAART |
27 (96.4%) |
24 (92.3%) |
0.604 |
| Previous AIDS |
0* |
4* (16%) |
0.11 |
| Nadir CD4+ T cell count, median (IQR) (cells/μl) |
329 (193–475) |
207 (95–434) |
0.116 |
| CD4+ cell count at baseline median (IQR)(cells/μl) |
573 (431–726) |
427 (334–594) |
0.038 |
| CD4+ cell count 3 mo post-vaccination, median (IQR)(cells/μl) |
567 (405–805) |
442 (351–760) |
0.23 |
| HIV VL at baseline, median (IQR)(log10/ml) |
1 (1–1.48) |
1 (1–1.29) |
0.442 |
| HIV VL 3 mo post-vaccination, median (IQR)(log10/ml) |
1 (1–1) |
1 (1–1.38) |
0.044 |
| HIV VL at baseline < L.D.L. |
20 (71.4%) |
14 (53.9%) |
0.26 |
| HIV VL 3 mo post-vaccination < L.D.L. | 24 (88.9%) | 15 (62.5%) | 0.046 |
*
data from 5 patients (4 and 1 in ID and IM group, respectively) are not available